RxDoctor Payments Data

Albert Shalomov, MD

Gastroenterology · Rego Park, NYNPI 1770775025

Payments from drug & device makers

$84,984in general payments, 2019–2025

Across 697 payments — averaging $121.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$59K
  • Phathom Pharmaceuticals, Inc.$9K
  • Ironwood Pharmaceuticals, Inc$6K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
  • Ardelyx, Inc.$2K
  • Takeda Pharmaceuticals U.S.A., Inc.$1K
  • plus $5K from 26 others

What the payments were for

  • Consulting fees$1,2501%
  • Speaking & faculty fees$66,36378%
  • Travel & lodging$1,4872%
  • Food & beverage$15,74319%
  • Education$340%
  • Other$1080%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$84,984 in reported general payments places this provider in the 90th percentile of 1,682 gastroenterology providers in New York.

See all gastroenterology providers in New York

Medicare billing

Part B allowed, 2024
$263,992
Medicare patients
631
Services billed
2,065

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ZenpepLipase/Protease/Amylase65$198,760
LinzessLinaclotide234$146,345
XifaxanRifaximin41$118,155
Humira PenAdalimumab13$104,677
IbsrelaTenapanor Hcl44$73,500
CreonLipase/Protease/Amylase28$50,953
VemlidyTenofovir Alafenamide17$26,947
Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate29$25,842
TrulancePlecanatide44$24,703
Mesalamine49$24,493
Dexlansoprazole DrDexlansoprazole94$23,730
ViberziEluxadoline12$19,009
VoqueznaVonoprazan Fumarate26$17,524
VireadTenofovir Disoproxil Fumarate12$13,742
Budesonide ErBudesonide16$13,466

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon, Viberzi$59,286$216,307274 claims
Aimmune Therapeutics, Inc.Zenpep$182$198,76065 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance, Plenvu$2,291$148,643128 claims
Ardelyx, Inc.Ibsrela$2,101$73,50044 claims
GileadVemlidy, Viread$864$40,68929 claims
Phathom Pharmaceuticals, Inc.Voquezna$8,828$17,52426 claims
Takeda Pharmaceuticals U.S.A., Inc.Dexilant$1,320$12,44944 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,682 gastroenterology providers in New York.

Other gastroenterology in Rego Park

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →